Current status on new anticoagulant and antithrombotic drugs and devices

Current Opinion in Pulmonary Medicine

Volumn 3, Issue 4, 1997, Pages 291-302

  Walenga, Jeanine M ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; BANDAGE; CEREBROVASCULAR DISEASE; CHILD; CORONARY ARTERY DISEASE; FEMALE; HUMAN; LUNG EMBOLISM; MALE; MAST SUIT; PREGNANCY; REVIEW; THROMBOPHLEBITIS;

ADULT; ANTICOAGULANTS; BANDAGES; CEREBROVASCULAR DISORDERS; CHILD; CORONARY DISEASE; FEMALE; FIBRINOLYTIC AGENTS; GRAVITY SUITS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; PREGNANCY; PULMONARY EMBOLISM; THROMBOPHLEBITIS;

EID: 0031183165     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199707000-00010     Document Type: Article

References (96)

1. Hull RD, Raskob GE, Hirsh J: The diagnosis of clinically suspected pulmonary embolism: practical approaches. Chest 1986, 89(suppl):417S-425S.
2. Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB: Prevention of venous thromboembolism. Chest 1995, 108:312S-334S.
3. Premmereur J: The use of low-molecular-weight heparins in cardiology. In New Anticoagulants for the Cardiovascular Patient. Edited by Piffarré R. Philadelphia: Hanley & Belfus; 1997:597-608.
4. Kalodiki E, Nicolaides AN: Low-molecular-weight heparin in the treatment of deep vein thrombosis. In New Anticoagulants for the Cardiovascular Patient. Edited by Pifarré R. Philadelphia: Hanley & Belfus; 1997:609-619.
5. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM: Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost 1996, 22(suppl 1):77-91.
6. Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L: Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995, 108:258S-275S.
7. Hirsh J, Hoak J: Management of deep vein thrombosis and pulmonary embolism. Circulation 1996, 93:2212-2245.
8. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, l'Espérance B, Demers C, Kassis J, Cruickshank M, Whitman L, Delorme F: Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996, 124:619-626.
9. Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, Nilsson P, Nylander G: Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996, 335:696-700.
10. Levine MN, Gent M, Hirsh J, Weitz J, Turpie AG, Powers P, Neemeh J, Willan A, Skingley P: Ardeparin (low-molecular-weight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. Arch Intern Med 1996, 156:851-856.
11. Heit JA, Berkowitz SD, Bona R, Cabanas V, Corson JD, Elliott CG, Lyons R (Ardeparin Arthroplasty Study Group): Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Thromb Haemost 1997, 77(1):32-38.
12. Lassen MR, Borris LC: Low molecular weight heparin for the prevention of deep vein thrombosis following orthopedic surgery. Curr Opin Pulm Med 1996, 2:300-304.
13. Planes A, Vochelle N, Darmon J-Y, Fagola M, Bellaud M, Huet Y: Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo. Lancet 1996, 348:224-228. Report on the prolonged use (35 days) of the LMW heparin enoxaparin to decrease the incidence of thrombotic syndrome after orthopedic surgery. This study showed that extended use of LMW heparin can markedly decrease thrombotic events.
14. Hull RD, Pineo GF, Brant RF: Effect of low molecular weight heparin versus warfarin sodium on mortality in long-term treatment of proximal vein thrombosis. Clin Appl Thrombosis/Hemostasis 1996, 2(suppl 1):S4-S11.
15. Dahl OE, Andreassen G, Aspelin T, Müller C, Mathiesen P, Nyhus S, Abdelnoor M, Solhaug J-H, Arnesen H: Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin®). Thromb Haemost 1997, 77:26-31.
16. Gårlund B for the Heparin Prophylaxis Study Group: Randomized, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 1996, 347:1357-1361.
17. The COLUMBUS Investigators: Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary embolism. Blood 1996, 88(Suppl 1):626a. Used on an outpatient basis, the LMW heparin reviparin was found to be effective in patients with established venous thrombosis, patients with pulmonary embolism, and patients without restrictions related to previous venous thrombosis. Thus, LMW heparin can be recommended as initial treatment for the full spectrum of patients with venous thrombosis.
18. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group: Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996, 347:561-568. Study of the LMW heparin dalteparin demonstrated the efficacy of this agent for the management of coronary syndrome. Compared with patients who received placebo, dalteparin-treated patients had a lower overall event rate.
19. Cohen M, Demers C, Gurfinkel E, Fromell G, Langer A, Turpie AGG, ESSENCE Group: Primary end point analysis from the ESSENCE trial: enoxaparin vs unfractionated heparin in unstable angina and non-Q wave infarction [abstract]. Circulation 1996, 94:I-554. Report on the use of the LMW heparin enoxaparin compared with heparin in the management of coronary syndrome. The outcome analysis for as long as 30 days was in favor of enoxaparin.
20. Antman EM, McCabe CH, Marble SJ, Cannon CP, Feldman R, Papuchis G, Moore PB: Dose ranging trial of enoxaparin for unstable angina: results of TIMI 11A [abstract]. Circulation 1996, 94:I-554.
21. Zidar J: New Insights in the prevention of thrombosis in coronary stents-the ENTICES trial and the role of enoxaparin [abstract]. Ann Hematol 1997, 74(suppl II):A152. Report on the combined use of the LMW heparin enoxaparin and the antiplatelet agent ticlopidine after elective stenting. This study demonstrated that subcutaneous LMW heparin with ticlopidine and aspirin decreased the incidence of stent thrombosis and ischemic events. Composite end points at 30 days were significantly in favor of enoxaparin compared with standard treatment.
22. Schiele FJ, Vuillemenot AR, Meneveau NF, Gupta SM, Xu CJ, Fontecave SJ, Cariou RG, Bassand J-PL: Initial experience of a sulphated pentasaccharide, a pure factor Xa inhibitor, in coronary angioplasty [abstract]. Circulation 1996, 94:I-742.
23. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, Lerner RG, Hall J, Sparling T, Brettell HR, et al.: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin In the treatment of proximal vein thrombosis. N Engl J Med 1992, 326:975-982.
24. Prandoni P, Lensing AWA, Büller HR, Carta M, Cogo A, Vigo M, Casara D, Ruol A, ten Cate JW: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992, 339:441-445.
25. Lopaciuk S, Meissner AJ, Filipecki S, Zawilska K, Sowier J, Cielsielski L, Bielawiec M, Glowinski S, Czestochowska E: Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial. Thromb Haemost 1992, 68:14-18.
26. Lindmarker P, Holmström M, Granqvist S, Johnsson H, Lockner D: Comparison of once-daily subcutaneous Fragmin with continuous Intravenous unfractionated heparin in the treatment of deep venous thrombosis. Thromb Haemost 1994, 72:186-190.
27. Simonneau G, Charbonnier B, Docousus H, Planchon B, Ninet J, Sie P, Selsiguen M, Combe S: Subcutaneous low molecular weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993, 153:1541-1546.
28. Raskob GE: Low molecular weight heparin for the prevention and treatment of venous thromboembolism. Curr Opin Pulm Med 1996, 2:305-310.
29. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, et al.: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996, 334:682-687. This clinical trial provided evidence to show that the LMW heparin enoxaparin can be used to treat established thromboembolic disorders. This study further demonstrated that the results of heparin and LMW heparin are comparable for the treatment of pre-existing thrombosis. This study had an important impact because it showed that pre-existing thrombotic disorders can be managed on an outpatient basis.
30. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M, et al.: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996, 334:677-681. This study demonstrated the efficacy of the outpatient use of LMW heparin for established thrombosis without monitoring, emphasizing that it may not be necessary to treat patients with heparin, which requires hospitalization. This would decrease health care costs because of early discharge of patients from the hospital.
31. Godwin J: Use of low molecular weight heparins in malignancy-related thromboembolic disorders: a clinical review. Clin Appl Thrombosis/Hemostasis 1996, 2(suppl 1):S28-S34.
32. Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebau M, Wiesel ML, Kher A, Barbier P, Cazenave JP: Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. Eur J Clin Invest 1988, 18:561-567.
33. Enke A, Breddin K: Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988, 75:1058-1063.
34. Godwin JE, Comp P, Davidson B, Rossi M, and the Normiflo™ Cancer Clinical Trial Group: Comparison of the efficacy and safety of subcutaneous RD heparin vs subcutaneous unfractionated heparin for the prevention of deep-vein thrombosis in patients undergoing abdominal or pelvic surgery for cancer [abstract]. Thromb Haemost 1993, 69(suppl):376.
35. Prandoni P, Lensing AWA, Büller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW: Deep-vein-thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992, 327:1128-1133.
36. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C: Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994, 71:7-11.
37. Salazar E, Izaguirre R, Verdejo J, Mutchinick O: Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J Am Coll Cardiol 1996, 27:1698-1703.
38. Hunt BJ, Doughty H-A, Majumdar G, Copplestone A, Kerslake S, Buchanan N, Hughes G, Khamashta M: Thromboprophylaxis with low molecular weight heparin (fragmin) in high risk pregnancies. Thromb Haemost 1997, 77:39-43.
39. Boda Z, Laszlo P, Rejtö L, Tornai I, Pfliegler G, Blaskó G, Rak K: Low molecular weight heparin as thromboprophylaxis in familial thrombophilia during the whole period of pregnancy. Thromb Haemost 1996, 76:124-128.
40. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M: Low-molecular-welght heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996, 128:313-318.
41. Forrat R, Ferrera R, Boissonnat P, Adeleine P, Dureau G, Ninet J, de Lorgeril M: High prevalence of thromboembolic complications in heart transplant recipients. Transplantation 1996, 61:757-762.
42. Walenga JM, Koza MJ, Lewis BE, Pifarré R: Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrambotic agents. Clin Appl Thrombosis/Haemostasis 1996, 2(suppl 1):S21-S27.
43. Greinacher A, Feigl M, Mueller-Eckhardt C: Crossreactivity studies between sera of patients with heparin associated thrombocytopenia and a new low molecular weight heparin, reviparin. Thromb Haemost 1994, 72:644-645.
44. Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C: Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb Haemost 1995, 74:886-892.
45. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia In patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
46. Fareed J, Walenga JM, Hoppensteadt D, Huan X, Nonn R: Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann N Y Acad Sci 1989, 556:333-353.
47. Fareed J, Callas DD, Hoppensteadt D, Jeske W, Walenga JM: Recent developments in antithrombotic agents. Exp Opin Invest Drugs 1995, 4:389-412.
48. Brieger D, Dawes J: Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997, 77:317-322.
49. Collignon F, Frydman A, Caplain H, Ozoux ML, Le Roux Y, Bouthier J, Thébault JJ: Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995, 73:630-640.
50. Eriksson BI, Söderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B: A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995, 73:398-401.
51. Boneu B: Low molecular weight heparin therapy: is monitoring needed? Thromb Haemost 1994, 72:330-334.
52. Samama M: Contemporary laboratory monitoring of low molecular weight heparins. Thromb Haemost 1995, 15:119-123.
53. Hoppensteadt DA, Jeske W, Fareed J: Laboratory monitoring of new anticoagulant and antithrombotic drugs. In New Anticoagulants for the Cardiovascular Patient. Edited by Pifarré R. Philadelphia: Hanley & Belfus; 1997:521-538.
54. Hawkins DW: Global economic perspective on the use of low molecular weight heparin. Clin Appl Thrombosis/Haemostasis 1996, 2(suppl 1):S40-S43.
55. Hull RD, Feldstein W, Stein PD, Pineo GF: Cost-effectiveness of pulmonary embolism diagnosis. Arch Intern Med 1996, 156:68-72.
56. Markwardt F: The development of hirudin as an antithrombotic drug. In New Anticoagulants for the Cardiovascular Patient. Edited by Pifarré R. Philadelphia: Hanley & Belfus; 1997:145-160.
57. Theroux P, Lidon R: Anticoagulants and their use in acute ischemic syndromes. In Textbook of Interventional Cardiology. Edited by Topol EJ. Philadelphia: WB Saunders; 1994:23-45.
58. Antman EM for the TIMI 9B Investigators: Hirudin in acute myocardial infarction: thrombolysis and thrombin Inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996, 94:911-921.
59. Flather M, Weitz J, Campeau J, Schuld R, Johnston M, Johnston M, Pogue J, Jessel A, Théroux P, Yusuf S, for the OASIS Pilot Study Investigators: Evidence for rebound activation of the coagulation system after cessation of intravenous anticoagulant therapy for acute myocardial ischemia [abstract]. Circulation 1995, 92:I-485.
60. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes [abstract]. N Engl J Med 1996, 335:775-782.
61. Serruys PW, Herrman J-PR, Simon R, Rutsch W, Bode C, Laarman G-J, van Dijk R, van den Bos AA, Umans VAWM, Fox KAA, et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995, 333:757-763.
62. Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P: Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet 1996, 347:635-639.
63. Eriksson BI, Mouret P, Kälebo P, Baur M, Ekman S, Lindbratt S, Bach D, Close P: Recombinant hirudin, CGP 39393 (™REVASC), is more effective than enoxaparin as prophylaxis of thromboembolic complications in patients undergoing total hip replacement [abstract]. Haemostasis 1996, 26(suppl 3):624. This study demonstrated the superior efficacy of r-hirudin over the LMW heparin enoxaparin, which was considered to be the gold standard for the prevention of DVT after orthopedic surgery. This study further showed that antithrombin agents are useful in prophylaxis for DVT.
64. Yonekawa Y, Handa H, Okamoto S, Kamijo Y, Oda Y, Ishikawa J, Tsuda H, Shimizu Y, Satoh M, Yamaguchi T, et al.: Treatment of cerebral infarction in the acute stage with synthetic antithrombin MD805: clinical study among multiple institutions. Archiv fur Japanische Chirurgie 1986, 55:711-726.
65. Jackson CV, Satterwhite J, Roberts E: Preclinical and clinical pharmacology of efegatran (LY294468): a novel antithrombin for the treatment of acute coronary syndromes. Clin Appl Thrombosis/Hemostasis 1996, 2:258-267.
66. Chamberlin JR, Lewis B, Leya F, Wallis D, Messmore H, Hoppensteadt D, Walenga JM, Moran S, Fareed J, McKiernan T: Successful treatment of heparin-associated thrombocytopenla and thrombosis using hirulog. Can J Cardiol 1995, 11:511-514.
67. Koza MJ, Lewis BE, Walenga JM, Pifarré R, Fareed J: Antithrombin agents in the management of heparin-induced thrombocytopenia. In New Anticoagulants for the Cardiovascular Patient. Edited by Pifarré R. Philadelphia: Hanley & Belfus; 1997:309-324.
68. Lewis BE, Walenga JM, Pifarré R, Fareed J: Argatroban in the management of patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. In New Anticoagulants for the Cardiovascular Patient. Edited by Pifarré R. Philadelphia: Hanley & Belfus; 1997:223-230.
69. Lewis BE, Grassman ED, Johnson SA, McKiernan TL: Pilot study of argatroban for angioplasty in patients with heparin allergy [abstract]. Circulation 1996, 94:I-375.
70. Lewis BE, Ferguson JJ, Grassman ED, Fareed J, Walenga J, Joffrion JL, Wrona L, Johnson SA, Schwarz RP Jr, McKiernan T: Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invas Cardiol 1996, 8:410-417. This study demonstrated that the LMW thrombin inhibitor argatroban can be effectively used as an anticoagulant during angioplasty. A direct comparison of argatroban and heparin showed that the achieved anticoagulant responses were similar. This study further showed the effective anticoagulation of heparin-compromised patients with a thrombin inhibitor.
71. Herrman J-P, Suryapranata H, Gabriel L, den Heijer P: Argatroban during percutaneous transluminal coronary angioplasty: results of a dose finding study [abstract]. Circulation 1996, 94:I-375.
72. Pötzsch B, Riess F-C, Madlener K, Völpel H, Müller-Berghaus G, Greinacher A: Recombinant hirudin as anticoagulant during cardiopulmonary bypass surgery [abstract]. Ann Hematol 1997, 74(suppl II):A153. Report on the effective use of r-hirudin in place of heparin for anticoagulation during open heart surgery with the cardiopulmonary bypass pump in heparin-compromised patients.
73. Riess F-C, Pötzsch B, Müller-Berghaus G: Recombinant hirudin as an anticoagulant during cardiac surgery. In New Anticoagulants for the Cardiovascular Patient. Edited by Piffarré R. Philadelphia: Hanley & Belfus; 1997:197-222. Provides clear data on the use of r-hirudin for cardiopulmonary bypass surgery. Also gives useful information on the application of antithrombin agents in the management of heparin-compromised patients who have cardiovascular surgery.
74. Riess FC, Löwer C, Seelig C, Bleese N, Kormann J, Müller-Berghaus G, Pötzsch B: Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovasc Surg 1995, 110:265-267.
75. The Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997, 336:153-162.
76. O'Gara P, Harrington R, Langer A, Halperin J, Fisher M, Feyzi J, Fuster V, CARS Investigators: Coumadin aspirin reinfarction study (CARS): relationship between event rates and INR [abstract]. Circulation 1996, 94:I-80. The combination of aspirin and warfarin failed to show superior efficacy compared with aspirin alone in the secondary prevention of cardiovascular death, re-infarction, or stroke. This trial may not have used optimal doses of the drugs.
77. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995, 108:231S-246S.
78. CAPRIE Steering Committee: A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339. This large clinical trial demonstrated that a new antiplatelet ADP-receptor antagonist, clopidogrel, is superior to 325 mg of aspirin for the management of overall events in arterial thrombosis. Clopidogrel is the orally active derivative of ticlopidine. It is devoid of granulocytopenic effects and can therefore be substituted for ticlopidine.
79. Vermylen J, Verhaeghe R: New platelet aggregation inhibitors. Hämostaseologie 1997, 17:43-48.
80. Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HF, Topol EJ, for the EPIC Investigators: Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996, 77:1045-1051.
81. Klootwijk P, Meij S, Melkert R, Simoons ML: Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE) [abstract]. J Am Coll Cardiol 1997, 29(suppl A):367A.
82. Ferguson JJ: EPILOG and CAPTURE trials halted because of positive interim results [news]. Circulation 1996, 93:637.
83. Lincoff AM, Tcheng JE, Califf RM, Cabot CF, Miller DP, Booth JE, Montague EA, Anderson KM, Topol EJ: Abciximab (c7E3 Fab, ReoPro) with reduced heparin dosing during coronary intervention: final results of the EPILOG trial [abstract]. J Am Coll Cardiol 1997, 29(suppl A):187A.
84. Cannon CP, Novotny WF, McCabe CH, Tischler MD, Borzak S, Henry TD, Feldman R, Hamilton S, Rothman JM, Braunwald E, and the TIMI Investigators: Evaluation of the oral glycoprotein IIb/IIIa antagonist Ro 48-3657 in patients with post acute coronary syndromes: primary results of the TIMI 12 trial [abstract]. Circulation 1996, 94:I-552.
85. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navett A, Smith JE, Worley SJ, for the Impact Investigators: Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation 1995, 91:2151-2157.
86. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, et al.: Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996, 27:536-542.
87. Rodgers A, MacMahon S: Antiplatelet therapy and the prevention of thrombosis. Aust N Z J Med 1996, 26:210-215.
88. Tcheng JE: Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996, 78:35-40.
89. Kowal-Vern A, Gamelli RL, Walenga JM, Hoppensteadt D, Sharp-Pucci M, Schumacher HR: The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical state. J Trauma 1992, 33:50-57.
90. Morris CL, Lutes R, Gruppo RA, Hashmi R, Harris R, Sambrano J, Morris JO: Prophylactic continuous infusion (CI) antithrombin III (AT-III) for prevention of regimen related toxicity (RRT) following bone marrow transplantation (BMT). Blood 1996, 88(suppl 1):117a.
91. Haire WD, Stephens LC, Ruby EI: Antithrombin III (AT3) treatment of organ dysfunction during bone marrow transplantation (BMT)-results of a pilot study [abstract]. Blood 1996, 88(suppl 1):456a.
92. Nurmohamad MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d'Azemar P, Büller HR, ten Carte JW, Hoek JA, van der Meer J, et al.: Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996, 75:233-238.
93. Hoppensteadt DA, Jeske W, Fareed J, Nicolaides AN: Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions. Int Angiol 1996, 15:39-46.
94. Bemmelen PS, Mattos MA, Faught WE, Mansour MA, Barkmeier LD, Hodgson KJ, Ramsey DE, Sumner DS: Augmentation of blood flow in limbs with occlusive arterial disease by intermittent calf compression. J Vasc Surg 1994, 19:1052-1058.
95. Wilson NV, Das SK, Kakkar W, Maurice HD, Smibert JG, Thomas EM, Nixon JE: Thrombo-embolic prophylaxis in total knee replacement J Bone Joint Surg 1992, 74-B:50-52.
96. Pifarré R, ed: New Anticoagulants for the Cardiovascular Patient. Philadelphia: Hanley & Belfus; 1997.